Dr. Rachmilewitz serves as the Chief Medical Officer at BioLineRx, formerly the Senior Vice President of Clinical Development at VBL Therapeutics. She is a clinical research physician executive with over 15 years of experience in Clinical Development and Medical Affairs roles in the Healthcare Industry previously working at, Teva, Novartis and Neuroderm. Dr. Rachmilewitz holds an M.D. from the Hadassah Medical School at the Hebrew University in Jerusalem.

As Head of Special Cargo at the International Air Transport Association (IATA), Dr Sonia Ben Hamida leads the development of the special cargo agenda, delivering standards, business processes, and solutions for the air cargo supply chain related to the transport of live animals, perishables, and temperature-sensitive cargo, and all other special cargo. Prior to joining IATA, Sonia held several roles in France where she spent 8 years driving innovation in the aerospace industry. Then she joined academia in 2019 as a lecturer and researcher at EPFL, the Swiss Federal Institute of Technology in Lausanne, and UNIGE, the University of Geneva. Over the past 12 years, I have built a strong expertise in project management, innovation, design, and business and systems modeling. Sonia holds an engineering degree in Aviation and Computer Science from the French Civil Aviation University - ENAC (France) and a PhD in Innovation from CentraleSupélec (France).

After 3 years in a clinical field as a registered nurse and almost 15 years of various positions in the pharmaceutical and medical device industries, in 2019 Nina joined Neuroderm as a Global Training and Patient Education Manager, mainly responsible for managing global company clinical trials training program and managing global CTEs (Clinical Trial Educators) activities and training.

Experienced Clinical Operations Manager with a demonstrated history of working in the pharmaceuticals industry. Broad experience in pharma products development, drug-device combinations, Oncology, Cardiology and Neurology, Good Clinical Practice (GCP), and Biotechnology. Strong operations professional with a MBA focused in Bio medical from College of Management.

Maayan Tsur, Director of Operations in Neuroderm, manages the company’s strategic vendors. During covid-19 pandemic Neuroderm had to adjust the management model of the clinical vendors in order to accommodate new constraints arising from the crisis period. Maayan led a risk management processes in Neuroderm and in external CRO which allowed identifying risks and mitigation plans, and worked with the team on its implementation. Maayan holds MSc in Bio medical studies and MBA from Tel Aviv university Neuroderm develops next-generation drug-device combination solutions for central nervous system disorders. NeuroDerm is an Israel-based, wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation

Dr. Nitsan Halevy is the Chief Medical Officer at Pluristem Therapeutics, where she leads clinical and regulatory activities. Nitsan has over 15 years of experience leading global clinical research and drug development projects. From an academic setting at Brigham and Women’s Hospital (Boston), Nitsan transitioned to industry, where she has held roles of increasing responsibility and scope at Novartis, Teva and Quark Pharmaceuticals. She holds an MD from Ben-Gurion University.

Hilla Debby Clinical Director at Icecure-Medical with over twenty years of experience in medical device industry. Her experience covers leading global clinical and regulatory activities. Holds a BsC in medical science.

Liat Ben David, Ph.D, Ms.C., Bs.C is a well experience Quality and Clinical Trials expert (Operational, Regulations, Quality; global & local); 20 years of experience in different organization types, in various therapeutic areas and various drug development phases. In her Ph.D., Liat focused on the development of a Quality Management model for clinical trials. A proactive, dynamic and innovative person; a strong believer in collaboration and teams' empowerment. A proven track record in developing effective processes and leading complex projects from idea to success. An experienced tutor / lecturer in professional related fields.

Boaz Albo is Head of the Medical Cannabis Treatment and Clinical Research Institute that was established in 2020 at the Sheba Medical Center, and also serves as the academic coordinator in leading academies for training programs of physicians, pharmacists and medical professions in the subject of "Treatment with Medical Cannabis" delivered by Sapir College, the Israeli Medical Association, the Hebrew University and Tel Aviv University. From 2014 till 2020 Boaz served as deputy to the director and as department head of R&D, Quality and Vocational Training in the Medical Cannabis Agency (IMCA of the Israeli Ministry of Health's. There, he took a major part in designing the policy and regulation for the emerging medical cannabis industry, including writing the clinical methodology and quality procedures for medical cannabis products. In his Academic training Boaz holds an M.Sc. graduate in life sciences and Biotechnology from the Hebrew University of Jerusalem and gained a vast experience in the biomed industry and research and development of innovative botanical products.

Professor Emerita Tel Aviv University (TAU), formerly Lily and Avraham Gildor Chair and Director of the Adams Super Center for Brain Studies. Currently, Director, Elton Laboratory for Molecular Neuroendocrinology. B.Sc. TAU, Ph.D., Weizmann Institute of Science, postdoc. MIT and Salk Institute. Associate Professor, Weizmann Institute, Fogarty-Scholar-in-Residence, NIH, Humboldt Awardee, Germany. Mentored >65 students. Published ~350 papers (h-index 79). Inventor of multiple patents including (NAP, Davuentide), a clinical drug candidate targeted at the rare disease indication, the ADNP syndrome. Discovered ADNP, essential for brain formation implicated in autism, schizophrenia, Alzheimer’s disease and cancer. NAP is the active site of ADNP. Multiple prizes including Teva Founders Prize, Landau Prizes and best applied scientist, TAU. Ex-President, Israel Society for Neuroscience (Honorary Member), Ex-Member, Council of Higher Education. Secretary, European Society for Neurochemistry. Editor-in-Chief, Journal of Molecular Neuroscience. Chief Scientific Officer, ATED Therapeutics.

Leukemia Patients Advocates Foundation host of: CML Advocates Network and MPN Advocates Network Israeli CML Patient’s Organisation Israeli Flute of Light- Home of blood cancers in Netanya, Israel Giora Sharf was diagnosed with chronic myeloid leukemia (CML) in March 2000 at the age of 47. After the initial shock of the diagnosis and some research on treatment options, he elected to wait for a clinical trial with a new agent, STI571. He joined the IRIS trial in June 2000 and after 7 months on interferon, he began taking Imatinib. After being PCR negative for 14 years he has stooped treatment more than 8 years ago and is on a Treatment Free Remission (TFR). Mr Sharf decided to use his experience to help other CML patients by founding the Israeli CML Patient's Organization in April 2001. What began with 7 local patients at a small hospital in the city of Netanya, Israel, has since grown to support more than 550 patients from all around the country. The main goal of the patient organization is to empower patients to be active and involved partners in their own disease management. In 2014, Mr Sharf founded a new Israeli blood cancer patient organization called "Flute of Light." The organization is a resource for patients in Israel with leukemia, lymphoma, and other blood disorders also helping patients deal with psychological challenges of diagnosis and treatments. In addition to his work with the Israeli Patient’s Organizations, Mr Sharf is a co-founder of the Leukemia Patients Advocates Foundation (LePAF) which is the host for 4 global blood cancer patients advocates networks including CML Advocates Network, which connects 128 leukemia patient groups from 95 countries and also MPN Patients Advocates. They are also involved in research, and Mr Sharf has led 2 global studies on Adherence and TFR for CML patients, which were presented at the ASH, EHA, ESH and other meetings and also published in scientific magazines like Leukemia. Mr Sharf serves on several advisory boards representing the patient’s perspective on CML and other blood cancers, and attends medical conventions, such as ASH and EHA, to report on updates for patients. He is also an alumni of EUPATI and has been a driver in opening a patient advocacy academy in Israel in 2021.

Mor Buchshtav, B.Sc., is the Director of Clinical & Regulatory Affairs at Medasense Biometrics Ltd. with over 12 years of experience in the medical device industry both from the clinical and the regulatory aspects. Mor is experienced with planning, executing, monitoring and analyzing bench tests, clinical studies and human factor studies, and has a record of successful regulatory submission of medical devices to Europe, United States, Canada, Brazil and various other jurisdictions. Her work is characterized by meticulous attention to details, dedication, drive to success and a love of the profession.

Julio discovered he had Hepatitis C by chance in 1994. He went through three year-long
courses on interferon treatment. These years were not easy and Julio struggled with
many challenges and questions and he looked for support.

When he realized there are no support groups or patient associations for liver patients in
Israel, Julio decided in 1998 to establish Hetz- the Israeli Organization for Liver Health.

Today Julio is cured from HCV. Nevertheless, he dedicates his life to supporting liver
patients and their families, strengthening Hetz's capacity to advocate for the PATIENTS'
RIGHT TO KNOW they have a liver disease, and the government's obligation to screen
and to treat them.

Actually Julio is directing HETZ and is representative of the patients in the National
Council of Liver of the Ministry of Health in Israel.

Efrat Hartog-David, VP of Regulatory Affairs and Quality Assurance at MeMed has over a decade of experience in Quality Assurance, Clinical and Regulatory Affairs. She has managed product lifecycle quality and regulatory submissions for clearances of numerous medical devices in the US, EU, China, and rest of the world. Before joining MeMed, Efrat was Regulatory Affairs Manager at GE Healthcare, responsible for leading and executing the global regulatory strategy for the Nuclear Medicine business. As part of her role at GE Healthcare she led a team responsible for providing leadership and guidance on global compliance, developing global regulatory strategies and plans, and preparing regulatory submissions and worldwide registrations. Efrat has also served as Regulatory Affairs specialist at Philips Healthcare, where she was the regulatory lead for programs aimed at introduction of new product, and played a key role in internal and external audits. Prior to that, Efrat served as a consultant for a wide range of medical device companies, focusing on clinical study design, quality system management, and regulatory strategy development and execution. Efrat holds a B.Sc. and Ph.D. in Biotechnology and Food Engineering from the Technion, Haifa, Israel.

Dr. Uri Heiman, Married with two teenage kids and a cat. Currently works for Laminate medical, Medical device startup as Clinical development Director responsible for training and establishing proper use of the devices the company provides, to support creation of innovative data and knowledge and to support further development of new devices. Previously have worked as a clinical specialist for local distributer in the field of cardiac surgery and ultrasound systems for cardiac use BSc. Biology, DVM Veterinary, Hebrew university MBA Tel Aviv university

Hadas Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.

Patient & Healthcare professional experience Lead at Pfizer | Advancing innovative & Data driven communication in healthcare | Lecturing on: Data driven & Omni-Channel marketing, Metaverse as an ecosystem in healthcare

Luba Vitkin Katz has over 10 years of experience in the clinical trials field, including a specialization in monitoring and documentation. Mrs. Vitkin Katz holds a B.Sc. in Life Science from the Hebrew University of Jerusalem, an MA in Science Education (cum laude) from Bar-Ilan University and is also a certified Clinical Research Associate (CRA) and completed a course of Auditing of Clinical Trials.

Adam Pitt is a Biological Threat Exclusion Coordinator (BTEC) for CBP in the Office of Field Operations/ Agriculture Programs and Trade Liaison/ Biological Threat Exclusion. As a BTEC, Mr. Pitt is charged with supporting and developing U.S. Customs and Border Protection (CBP) operational capacity and capability in preventing tools of agro/bio-terrorism from entering the U.S. Mr. Pitt has more than 18 years of public service with CBP and the National Institutes of Health (NIH), and has worked in a variety of environments, including air passenger, cargo, and express consignment carrier locations.

Sean Smith is a Biological Threat Exclusion Coordinator (BTEC) for CBP in the Office of Field Operations/ Agriculture Programs and Trade Liaison/ Biological Threat Exclusion. As a BTEC, Mr. Smith is charged with supporting and developing U.S. Customs and Border Protection (CBP) operational capacity and capability in preventing tools of agro/bio-terrorism from entering the U.S.  Mr. Smith has more than 17 years of public service with CBP, and has worked in a variety of environments, including on the southern land border, maritime, air passenger, and cargo locations.  He has also been able to assist in several past domestic and international CBP disaster recovery operations.

Rochelle has held various positions within Innovative R&D, Global Clinical Operations at Teva Pharmaceuticals, for the last 11 years. She has over 30 years of experience in the healthcare industry, and holds a BBA in International Marketing, and an MBA in Entrepreneurship.

Elvira Suniega-Tolentino is the Clinical Project Manager Team Leader for Singapore at the Nestlé Clinical Research Unit, responsible for end-to-end clinical project management and operational activities of Nestlé corporate clinical trials serving all Business Units. At the Clinical Research Unit, she is also leading the Vendor/Out-sourcing activities where she drives strategic partnerships with CROs, Universities, Laboratories, etc. Prior to joining Nestlé, Elvira was the Area Clinical Operations Manager for Abbott Nutrition R&D, Asia Pacific Center in Singapore for 11 years. Over the years, she has sharpened her expertise in the industry, bringing in thoughtful and strong competency into Nestlé’s clinical projects.  The combination of her expertise, leadership and passion for innovation strongly supports the continuous improvement and excellence of Nestlé’s clinical research activities to further unlock the power of food to enhance the quality of life for every consumers, today and for generations to come.

Yael Genosar, Associate Director of Clinical Supply Chain at OPKO Biologics Israel. Experienced Clinical Supply Chain manager with a four years' experience of managing supply chain in a global clinical trial. Previously Project Manager at Hot Mobile a wireless telecommunications company, leading technologies projects.

Mr. Bennett has worked in clinical development for approximately 20 years and has worked for WCT since September 2021. He began his career in clinical research in a phase 1 clinic and soon after held roles as a Clinical Research Associate on both early and late phase clinical trials with responsibilities for data validation and site management. This solid base experience in ICH-GCP was further supplemented with broad operational knowledge regarding the conduct of clinical trials when he was appointed as a Clinical Trial Manager of Phase I, II and II trials within global programs. Building on this operational grounding, he has latterly (seven years) held positions where he has led cross-functional project teams within clinical research and has been responsible for project strategies, clinical development plans, clinical trial methodologies (concept/design), protocol authorship and the transformation of the scientific endeavor into an operationalized activity. Through being part of R&D leadership teams, he has contributed to business management and the development of operating models and outsourcing strategies. He has been responsible for representing pipeline projects in R&D governance boards and holds experiences throughout the drug development life cycle.

Paul has 28 years’ experience working in Life Sciences; 7 researching Respiratory indications (asthma, COPD, PPH) and 9 years in Clinical Research for emerging Biotechs managing programs in across Respiratory, Oncology, Gastro-Enterology, Endocrinology therapeutic areas. Over the last 12 years Paul has specialised in eClinical, working for CROs and technology providers with a focus on clinical trial processes, ICH GCP, the use of technology to solve industry problems, and is also an SME in RBQM.

Sascha held numerous positions in business development and operations, most notably in global Commercial Operations AMERICAS & EMEA at Marken and VP Business Development at Sharp Clinical Services, where he formed a new business development team and implemented novel services. Sascha is a subject matter expert of a broad range of services along the clinical supply chain such as Direct-to-Patient, labelling & packaging, cell & gene therapies , and global distribution strategies. Sascha studied economics and holds a MBA in International Management and Leadership. He has been a long-term member of the ISPE Investigational Product community, contributed to the development of several Good Practice Guides and was a member of the European IP Steering Committee. At SanaClis Sascha is leading global business development and acts as Country Head Germany.

Dr. Gedo draws upon 25 years of experience as a marketing and business strategy expert serving in academic, government, and industry functions. Dr. Gedo’s extensive expertise in international marketing, branding, entrepreneurship, and business strategy has served him in his various leadership roles. He has contributed to a wide range of branding, strategic planning, and market penetration activities as a senior manager or executive director of major companies in a variety of industries, including the pharmaceutical industry. Dr. Gedo founded BOL Pharma and served as CEO and founding Board member, during his period he grew the company from four employees to become the largest cannabis company in Israel which owned around 50% market share. He served as executive director at Lundbeck Israel and Maccabi Healthcare which is the second largest health medical organization in Israel. As a consultant, Dr. Gedo provided services to companies in the medical, nutrition, and pharmaceutical industries. In addition to his business and consulting practice, Dr. Gedo has served as the head of the marketing department and other faculty positions of several colleges in Israel such as the Max Stern Yizrael Valley College and IDC Herzelia College and has guest lecturer in the Department of Business Administration of Shanghai University. He has taught undergraduate and graduate-level courses in global marketing, business strategy, innovation, and entrepreneurship. Dr. Gedo received his Ph.D. in Economics from Manchester Business School (UK) and an MBA from Ben Gurion University (Israel). He completed a B.Sc. in Molecular Biology at Bar Ilan University (Israel).